TKI-话题@MedSci

#TKI#

128篇内容 | 3880人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2199165, encodeId=896f2199165dd, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【Blood Reviews】慢性髓性白血病综述：从生物学到治疗, objectType=article, longId=821943, objectId=5713821943f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/filling-medical-history-XZB9RVX.jpg, objectUrl=/article/show_article.do?id=5713821943f3, replyNumber=0, likeNumber=83, createdTime=2024-04-18, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=5713821943f3, moduleTitle=【Blood Reviews】慢性髓性白血病综述：从生物学到治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5713821943f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2194158, encodeId=2d962194158ed, content=<a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=【Leukemia】二代TKI一线治疗CML的长期随访：关注不耐受和耐药的管理, objectType=article, longId=817496, objectId=83bc81e496c9, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-working-in-a-hospital-PSQT2U3.jpg, objectUrl=/article/show_article.do?id=83bc81e496c9, replyNumber=0, likeNumber=65, createdTime=2024-03-19, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=83bc81e496c9, moduleTitle=【Leukemia】二代TKI一线治疗CML的长期随访：关注不耐受和耐药的管理, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=83bc81e496c9)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2188905, encodeId=a0dc218890518, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a> <a href='/topic/show?id=9b5453e2447' target=_blank style='color:#2F92EE;'>#慢性髓性白血病#</a> <a href='/topic/show?id=20b24899a7' target=_blank style='color:#2F92EE;'>#CML#</a>, objectTitle=【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）, objectType=article, longId=814228, objectId=a49081422881, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/doctor-filling-form-U2MAYRK.jpg, objectUrl=/article/show_article.do?id=a49081422881, replyNumber=0, likeNumber=77, createdTime=2024-02-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a49081422881, moduleTitle=【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a49081422881)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2164864, encodeId=8ee5216486473, content=<a href='/topic/show?id=50d6e0215a' target=_blank style='color:#2F92EE;'>#ESMO#</a>：这次会议将对肺癌领域的多项研究数据进行更新和展示。特别是针对<a href='/topic/show?id=94c265920c' target=_blank style='color:#2F92EE;'>#EGFR突变#</a>阳性非小细胞肺癌（<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a>）的靶向治疗，将成为备受关注的焦点。随着EGFR酪氨酸激酶抑制剂（<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>）的研发成功，一代/二代/三代EGFR-TKI已经被批准上市用于EGFR突变的晚期NSCLC治疗，<a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a>是唯一具有确切总生存期（<a href='/topic/show?id=3bf913489f4' target=_blank style='color:#2F92EE;'>#OS#</a>）数据的三代EGFR-TKI药物。, objectTitle=2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！, objectType=article, longId=797861, objectId=a343e978611e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20231023/7e658cfe5226459cbf06b6d0e070b22e.jpg, objectUrl=/article/show_article.do?id=a343e978611e, replyNumber=0, likeNumber=141, createdTime=2023-10-25, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=a343e978611e, moduleTitle=2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a343e978611e)], followStatus=false, userIsMember=true, type=1, lengthMark=1), GetTopicListResponse(id=1384259, encodeId=60921384259d6, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=科学管理ALK-TKI不良反应助力ALK+NSCLC长生存, objectType=article, longId=734757, objectId=a1cee34757b5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a1cee34757b5, replyNumber=0, likeNumber=105, createdTime=2022-08-06, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a1cee34757b5, moduleTitle=科学管理ALK-TKI不良反应助力ALK+NSCLC长生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a1cee34757b5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384258, encodeId=4f701384258ef, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, objectType=article, longId=734225, objectId=0acbe3422547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0acbe3422547, replyNumber=0, likeNumber=84, createdTime=2022-08-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0acbe3422547, moduleTitle=Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0acbe3422547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384257, encodeId=435f138425ecf, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后, objectType=article, longId=729557, objectId=269be2955716, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=269be2955716, replyNumber=0, likeNumber=113, createdTime=2022-06-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=269be2955716, moduleTitle=Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=269be2955716)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384256, encodeId=713d13842564e, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, objectType=article, longId=727759, objectId=e5e5e27759c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e5e5e27759c4, replyNumber=0, likeNumber=131, createdTime=2022-05-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e5e5e27759c4, moduleTitle=J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e5e5e27759c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384255, encodeId=6bb81384255eb, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, objectType=article, longId=723407, objectId=bf1be2340744, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bf1be2340744, replyNumber=0, likeNumber=74, createdTime=2022-04-05, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bf1be2340744, moduleTitle=Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bf1be2340744)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384254, encodeId=387f13842545c, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, objectType=article, longId=300760, objectId=f451300e604a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f451300e604a, replyNumber=0, likeNumber=73, createdTime=2022-03-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f451300e604a, moduleTitle=Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f451300e604a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384252, encodeId=06541384252a3, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, objectType=article, longId=295276, objectId=d9be2952e62d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9be2952e62d, replyNumber=0, likeNumber=80, createdTime=2022-02-10, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9be2952e62d, moduleTitle=Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9be2952e62d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384253, encodeId=32d2138425330, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, objectType=article, longId=295260, objectId=94052952604f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94052952604f, replyNumber=0, likeNumber=63, createdTime=2022-02-09, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94052952604f, moduleTitle=Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94052952604f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384251, encodeId=5c07138425126, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：一线TKI联合局部放疗可改善老年NSCLC伴有寡转移患者预后, objectType=article, longId=295051, objectId=4a0729505129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4a0729505129, replyNumber=0, likeNumber=111, createdTime=2022-02-04, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4a0729505129, moduleTitle=Front Oncol：一线TKI联合局部放疗可改善老年NSCLC伴有寡转移患者预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a0729505129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384250, encodeId=7d931384250dc, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, objectType=article, longId=294620, objectId=03df29462025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=03df29462025, replyNumber=0, likeNumber=112, createdTime=2022-01-26, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=03df29462025, moduleTitle=Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=03df29462025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384249, encodeId=2ebc1384249a7, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, objectType=article, longId=294112, objectId=1b49294112ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1b49294112ae, replyNumber=0, likeNumber=95, createdTime=2022-01-18, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1b49294112ae, moduleTitle=Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1b49294112ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384248, encodeId=0481138424898, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=0, createdTime=2022-01-16, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384247, encodeId=3ba9138424e36, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, objectType=article, longId=293109, objectId=d234293109ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d234293109ad, replyNumber=0, likeNumber=81, createdTime=2021-12-31, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d234293109ad, moduleTitle=Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d234293109ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384246, encodeId=dba61384246d8, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, objectType=article, longId=292260, objectId=b801292260d3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b801292260d3, replyNumber=0, likeNumber=89, createdTime=2021-12-21, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b801292260d3, moduleTitle=Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b801292260d3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384245, encodeId=531d1384245f6, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）, objectType=article, longId=292145, objectId=e37d29214556, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e37d29214556, replyNumber=0, likeNumber=102, createdTime=2021-12-19, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e37d29214556, moduleTitle=盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e37d29214556)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1384244, encodeId=9b2513842446d, content=<a href='/topic/show?id=14bb1e503a0' target=_blank style='color:#2F92EE;'>#TKI#</a>, objectTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, objectType=article, longId=292019, objectId=0498292019ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0498292019ed, replyNumber=0, likeNumber=91, createdTime=2021-12-18, rootId=0, userName=lsj628, userId=b73f484, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0498292019ed, moduleTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0498292019ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

TKI

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#TKI# #慢性髓性白血病# #CML#

【Blood Reviews】慢性髓性白血病综述：从生物学到治疗

2024-04-18发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#慢性髓性白血病# #TKI#

【Leukemia】二代TKI一线治疗CML的长期随访：关注不耐受和耐药的管理

2024-03-19发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#TKI# #慢性髓性白血病# #CML#

【BJH】慢性期CML患者停用TKI后分子学复发的动力学（附专家点评）

2024-02-23发表于上海

(审核中...)

前往app查看评论内容

全文收起 #ESMO#：这次会议将对肺癌领域的多项研究数据进行更新和展示。特别是针对#EGFR突变#阳性非小细胞肺癌（#NSCLC#）的靶向治疗，将成为备受关注的焦点。随着EGFR酪氨酸激酶抑制剂（#TKI#）的研发成功，一代/二代/三代EGFR-TKI已经被批准上市用于EGFR突变的晚期NSCLC治疗，#奥希替尼#是唯一具有确切总生存期（#OS#）数据的三代EGFR-TKI药物。

2023 ESMO |【奥希替尼】一线治疗地位无可撼动，新方案带来更多惊喜！

2023-10-25发表于上海

lsj628 (审核中...)

前往app查看评论内容

#TKI#

科学管理ALK-TKI不良反应助力ALK+NSCLC长生存

2022-08-06

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Lancet oncol：信迪利单抗+IBI305+化疗治疗EGFR TKI治疗后进展的EGFR突变型NSCLC

2022-08-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Ann Oncol：Pimitespib可显著改善TKI难治性晚期胃肠道间质瘤的预后

2022-06-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Clin Oncol：国产三代EGFR-TKI阿美替尼挺进晚期EGFR突变NSCLC患者一线治疗

2022-05-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：术后早期复发肝细胞癌使用TKI联合抗PD-1治疗的疗效

2022-04-05

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Oncologist：全球多中心真实世界探索EGFR-TKIs治疗罕见EGFR突变NSCLC患者的疗效

2022-03-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Transl Lung Cancer Res: 在EGFR突变晚期NSCLC患者使用EGFR-TKI治疗失败后，化疗-抗血管生成对比化疗-免疫治疗联合治疗的疗效

2022-02-10

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Transl Lung Cancer Res: 广医一院团队：第一代EGFR-TKIs(吉非替尼、厄洛替尼和埃克替尼)术后辅助治疗NSCLC伴有EGFR敏感突变患者的疗效比较

2022-02-09

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：一线TKI联合局部放疗可改善老年NSCLC伴有寡转移患者预后

2022-02-04

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：EGFR-TKI联合胸腺素治疗EGFR突变的晚期非小细胞肺癌(NSCLC)可改善患者的预后

2022-01-26

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Front Oncol：TACE联合ICIs+TKIs治疗不可切除肝细胞癌的疗效

2022-01-18

lsj628 (审核中...)

前往app查看评论内容

#TKI#

J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控

2022-01-16

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Signal Transduct Target Ther：PD-1抑制剂Toripalimab（特瑞普利单抗）联合化疗二线治疗晚期EGFR突变NSCLC一线TKI进展后显示良好抗肿瘤疗效和可控安全性

2021-12-31

lsj628 (审核中...)

前往app查看评论内容

#TKI#

Clin Cancer Res：Nivolumab对比卡铂+培美曲塞治疗EGFR突变NSCLC患者一线TKI治疗进展后的疗效

2021-12-21

lsj628 (审核中...)

前往app查看评论内容

#TKI#

盘点国产第三代EGFR-TKI之阿美替尼（almonertinib）

2021-12-19

lsj628 (审核中...)

前往app查看评论内容

#TKI#

BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好

2021-12-18

科室
- - 订阅+
  - 更多科室
工具
服务